Improvements in care needed for patients with progressive lung disease
A national roundtable provides direction for key components that should be included in national strategies to optimize care for patients with progressive fibrosing interstitial lung disease (PF-ILD).
The Institute for Health Economics (IHE) conducted an invitational, virtual policy roundtable on progressive fibrosing interstitial lung disease (PF-ILD) on November 20th, 2020. This policy roundtable sought to gain multi-stakeholder consensus on policy directions needed to optimize care for PF-ILD patients that could inform national strategies to address this disease.
Progressive, fibrosing interstitial lung disease is a rapidly progressing illness, 50% of patients die, usually from lung failure, between two and five years from the time of diagnosis, with younger patients typically surviving longer. Optimal management of PF-ILD requires access to numerous specialists and specialty services which makes care navigation complex, particularly for those with less independence or functional loss from disease.
Key actions identified at the roundtable to optimize the future care of patients, included:
- Better surveillance to identify patients and design and target services to needs.
- Accelerated development and implementation of multi-disciplinary guidance that addresses the full continuum of care.
- Broad adoption and investment in patient navigators to support patients and families.
- Awareness and informational resources needed for community-based providers
- Implementation of hub-and-spoke models of care, increasing use of primary care physicians in diagnosis and management.
- Implement innovative financing approaches to ensure appropriate care is provided.
“The Institute of Health Economics is pleased to have been able to bring diverse stakeholders together to collectively identify policy options to improve health service delivery for patients living with progressive fibrosing interstitial lung disease, “said Dr. Chris McCabe, the Institute of Health Economics Executive Director and CEO. ”We are very grateful for the thoughtful input from clinicians, patient representatives, and policy makers in advancing this work which we hope will inform ongoing strategies in service design and research.”
“Boehringer Ingelheim Canada is committed to exploring innovations in health service delivery that are evidence-informed and with input from those directly involved in delivering and receiving care”, said Annie Beauchemin, Executive Director, Patient Access and Healthcare Affairs Solutions.. “We welcome the opportunity to support the Institute of Health Economics in gathering evidence in this important area and facilitating deliberations that we hope can lead to improving the lives of those living with this challenging disease.”
The full report is available at: https://www.ihe.ca/advanced-search/optimizing-care-for-patients-with-progressive-fibrosing-interstitial-lung-disease-pf-ild-
This invitational forum was conducted by the Institute of Health Economics (IHE) and was supported by and developed in partnership with Boehringer Ingelheim (Canada) Ltd./Ltée.
John Sproule, Senior Policy Director, Institute of Health Economics,
Ph: (780) 448-4881
The Institute of Health Economics (IHE) is an independent, not-for-profit research organization that conducts health economics and health services research, performs health technology assessments, and convenes health policy engagements for a wide variety of public and private health system stakeholders. Visit us at https://www.ihe.ca to learn more.
Boehringer Ingelheim Canada (Ltd.)
Making new and better medicines for humans and animals is at the heart of what we do. Our mission is to create breakthrough therapies that change lives. Since its founding in 1885, Boehringer Ingelheim is independent and family-owned. We have the freedom to pursue our long-term vision, looking ahead to identify the health challenges of the future and targeting those areas of need where we can do the most good.As a world-leading, research-driven pharmaceutical company, more than 51,000 employees create value through innovation daily for our three business areas: Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. In 2019, Boehringer Ingelheim achieved net sales of 19 billion euros. Our significant investment of almost 3.5 billion euros in R&D drives innovation, enabling the next generation of medicines that save lives and improve quality of life. We realize more scientific opportunities by embracing the power of partnership and diversity of experts across the life-science community. By working together, we accelerate the delivery of the next medical breakthrough that will transform the lives of patients now, and in generations to come.
The Canadian headquarters of Boehringer Ingelheim was established in 1972 in Montreal, Quebec and is now located in Burlington, Ontario. Boehringer Ingelheim employs approximately 600 people across Canada.